Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells
Pakistan Journal of Pharmaceutical Sciences · 01.02.2027
DOI: 10.36721/pjps/2026.40.16269.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 23.10.2026. Verfasst von Ting Wang. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Background
Ligustrazine is a pivotal active component of Ligusticum wallichii Franch; it is used clinically for treating cardiovascular diseases. Derivatization of ligustrazine might promote its biological activities and bioavailability.
Objectives
A series of ligustrazine-acylhydrazone derivatives (TMPAD-1–TMPAD-13) were synthesized and their inhibitory activity against A549 cells was investigated.
Methods
These derivatives were synthesized by condensing aromatic aldehydes with ligustrazine-based hydrazides to form acylhydrazone bonds and their chemical structures were characterized through a combination of spectral methods, including Fourier transform infrared (FT-IR) spectroscopy, electrospray ionization high resolution mass spectrometry (ESI-HRMS), 1H and 13C nuclear magnetic resonance (NMR) spectra.
Results
In-vitro experimental results displayed that TMPAD-2 exhibited marked inhibitory activity against A549 cells as shown by impeding cell proliferation (IC50 = 48.08 μmol/L), colony formation (colony forming efficiency ≤ 1.5 ± 0.02%), invasion and migration, enhancing tumor necrosis factor (TNF)-α and reactive oxygen species (ROS) levels, decreasing interleukin (IL)-6 and mitochondrial membrane potential (MMP) levels, hindering cell cycle progression and inducing apoptosis. RNA-sequencing (RNA-seq) analysis disclosed 17 lung cancer-related differentially expressed genes (DEGs). These results were statistically supported with significant p-value.
Conclusion
These results suggest that dysregulation of the cyclin–cyclin-dependent kinase (CDK)–cyclin-dependent kinase inhibitor (CKI) regulatory network is primarily responsible for the inhibitory action of TMPAD-2 on A549 cells. Current findings might provide valuable insights for further development of ligustrazine derivatives as novel anticancer agents.
Zitieren
APA
Wang, T. (2027). Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.16269.1
Vancouver
Wang T. Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells. Pakistan Journal of Pharmaceutical Sciences. 2027. doi:10.36721/pjps/2026.40.16269.1
BibTeX
@article{Wang2027,
author = {Wang, Ting},
title = {Synthesis and characterization of ligustrazine-acylhydrazone derivatives and their inhibitory activity against human lung cancer A549 cells},
journal = {Pakistan Journal of Pharmaceutical Sciences},
year = {2027},
doi = {10.36721/pjps/2026.40.16269.1}
}
EUVIMED